Reimbursement Review Reports

The latest CADTH Reimbursement Review reports are posted to this page. CADTH reimbursement reviews are comprehensive assessments of the clinical effectiveness and cost-effectiveness, as well as patient and clinician perspectives, of a drug or drug class. The assessments inform non-binding recommendations that help guide the reimbursement decisions of Canada's federal, provincial, and territorial governments, with the exception of Quebec. Implementation advice and funding algorithms are provided where applicable.

Brand Name Generic Name Therapeutic Area Recommendation Type Project Status Sort descending Date Submission Received Date Recommendation Issued
BuTrans Buprenorphine transdermal patch Pain, persistent (moderate intensity) Cancelled
Targin Oxycodone / naloxone Pain, Moderate to severe and relief of opioid-induced constipation Cancelled
Onivyde Nanoliposomal Irinotecan Cancelled
Cyramza Ramucirumab Cancelled
Alecensaro Alectinib Locally advanced or metastatic ALK+ NSCLC (first line) Reimburse with clinical criteria and/or conditions Complete
Nitisinone nitisinone Hereditary tyrosinemia type 1 Reimburse with clinical criteria and/or conditions Complete
Lapelga Pegfilgrastim Febrile neutropenia N/A Complete
Trelegy Ellipta fluticasone furoate umeclidinium vilanterol Chronic obstructive pulmonary disease (COPD) Reimburse with clinical criteria and/or conditions Complete
Gazyva Obinutuzumab Follicular Lymphoma (previously untreated) Do not reimburse Complete
Blincyto Blinatumomab Acute Lymphoblastic Leukemia (pediatric) Reimburse with clinical criteria and/or conditions Complete